FIELD: medicine.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a use of a compound of formula IA or a pharmaceutically acceptable salt thereof
(IA), as well as using a combination of said compound and an additional therapeutic agent selected from: compounds IB, IC, neuroleptic agent, antiglutamatergic means, antiglutamatergic agent, dopamine-reducing agent, acetylcholinesterase inhibitor, for preventing or treating hyperkinetic movement disorder caused by Huntington's disease, Wilson's disease, Tourette's syndrome, restless leg syndrome or tardive dyskinesia.
EFFECT: group of inventions enables using compound IA and a combination of said compound with said therapeutic agents for a new purpose.
20 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF (−)-α-DIHYDROTETRABENAZINE OR A COMBINATION THEREOF WITH (+)-α-DIHYDROTETRABENAZINE IN THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDER, AS WELL AS CORRESPONDING METHODS | 2018 |
|
RU2768738C2 |
| TETRABENAZINE TRANSDERMAL DELIVERY DEVICE | 2020 |
|
RU2838380C1 |
| (+)-ALPHA-DIHYDROTETRABENAZINE FOR USE IN TREATMENT OF MOTOR DISORDER | 2018 |
|
RU2771164C2 |
| TETRABENAZINE TRANSDERMAL DELIVERY DEVICE | 2019 |
|
RU2800536C2 |
| PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2783865C2 |
| METHOD FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL | 2015 |
|
RU2702101C2 |
| NEW USING (R)-(-)-2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2001 |
|
RU2278663C2 |
| NOVEL USE OF SUBSTITUTED AMINOMETHYLCHROMANS | 2002 |
|
RU2322443C2 |
| CARBAMATE DERIVATIVES FOR USING IN PROPHYLAXIS OR TREATMENT IN MOTION DISORDER | 2002 |
|
RU2294739C2 |
| DIHYDROTETRABENAZENES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2005 |
|
RU2365590C2 |
